3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
29
Ovarian Neoplasms
2
Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Locoregional Recurrence
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Granulosa cell tumor of the ovary
1
Endometrial Neoplasms
1
Carcinoma, Ductal
1
Breast Carcinoma In Situ
1
Anatomic Stage III Breast Cancer AJCC v8
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Breast Carcinoma
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
26
Paclitaxel
25
Carboplatin
19
Bevacizumab
13
Specimen Handling
11
Magnetic Resonance Spectroscopy
9
Doxorubicin
8
Cisplatin
8
Taxes
7
Biopsy
7
olaparib
6
lenvatinib
6
Fulvestrant
6
durvalumab
5
dostarlimab
5
Nivolumab
5
Megestrol Acetate
5
Letrozole
5
Gemcitabine
5
Docetaxel
5
trastuzumab deruxtecan
4
Trastuzumab
4
Tirzepatide
4
Progestins
4
Medroxyprogesterone Acetate
4
Fluorouracil
4
palbociclib
3
ipatasertib
3
atezolizumab
3
abemaciclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
exemestane
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled